BECOME MEMBER SUPPORT
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second line therapy in head and neck cancer.
Phase 3 randomized study for evaluation of physician choice Rx (Docetaxel or triple metronomic) versus best supportive care as second-line or beyond therapy in head and neck cancer.
Video and slides
CRSF Asco list of publications 
Ongoing studies